文献速递外周动脉疾病静脉血栓栓塞

外周动脉疾病患者血管内介入术后静脉血栓栓塞的发生率

Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2022-09-29

基于美国医保住院索赔数据,纳入2008年1月1日至2015年9月30日期间接受外周血管介入(PVI)的66岁以上成人31,593例,随访365天。术后30天和90天深静脉血栓累积发生率分别为3.8%和4.8%,肺栓塞分别为0.9%和1.2%;女性深静脉血栓风险略高于男性。

要点

  • PVI术后90天深静脉血栓累积发生率为4.8%,肺栓塞为1.2%。
  • 女性较男性深静脉血栓风险略高:30天风险差0.007(P<.01),90天风险差0.008(P=.02)。
  • 90天发生VTE的患者中970例(55%)无抗血小板或抗凝处方配药记录。

核心结论

  • PVI术后VTE发生率较高,女性深静脉血栓风险增加。
  • 女性在PVI后接受抗凝药处方的可能性较低。
  • 未来需研究PVI后VTE风险增加的相关变量,并确定提高双联抗血小板或抗凝处方依从性的策略以降低VTE风险。

研究设计与样本

  • 基于美国医保住院索赔数据的回顾性队列研究,纳入2008年1月1日至2015年9月30日期间接受PVI的66岁以上成人31,593例,随访365天。
  • VTE事件通过国际疾病分类第9版诊断代码识别,采用Aalen-Johansen估计量计算协变量标准化的30天和90天累积发生率,以死亡为竞争风险。
  • 性别差异采用Gray检验;抗血小板或抗凝处方配药定义为血管内介入前14天至VTE事件日期之间的任何配药,通过配药日期和供应天数评估持续性,未评估非处方药(即阿司匹林)。

主要发现

  • 31,593例患者平均年龄76.8±7.4岁,46%为男性,12%有VTE病史。
  • 术后30天和90天深静脉血栓累积发生率分别为3.8%和4.8%,肺栓塞分别为0.9%和1.2%。
  • 女性较男性深静脉血栓风险略高:30天风险差0.007(P<.01),90天风险差0.008(P=.02);肺栓塞风险无性别差异。
  • 90天发生VTE的患者中970例(55%)无抗血小板或抗凝处方配药记录;假设所有患者均服用阿司匹林,仅15%的VTE患者持续服用处方双联抗血小板药物。
  • 90天发生VTE的患者中,女性接受抗凝药处方的可能性较低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Venous thromboembolism (VTE) is a well-known postoperative complication; however, the incidence of VTE after peripheral vascular intervention (PVI) has not been well described. Despite the minimally invasive nature of these procedures, the patients undergoing PVI have significant risk factors for the development of VTE. In the present study, our objective was to describe the short-term incidence of VTE after PVI, identify differences between sexes, and examine the periprocedural antiplatelet and anticoagulation regimens. METHODS: We identified adults (age >66 years) who had undergone PVI from January 1, 2008 to September 30, 2015 from the inpatient Medicare claims data. The patients were followed for 365 days after the procedure. VTE events during follow-up were identified using the International Classification of Diseases, 9th revision, diagnosis codes. The covariate-standardized 30- and 90-day cumulative incidence of VTE events, overall and stratified by sex, were estimated using Aalen-Johansen estimators, accounting for death as a competing risk. Differences in sex between females and males were identified using Gray's test. Any antiplatelet or anticoagulant prescription fill was defined as any fill from 14 days before the endovascular intervention through the date of the VTE event. Persistence with antiplatelet and anticoagulant therapy was assessed by creating daily logs of antiplatelet and anticoagulant coverage using the dispensing dates and days of supply. Over-the-counter medications (ie, aspirin) were not evaluated. RESULTS: We identified 31,593 qualifying patients with a mean age of 76.8 ± 7.4 years. Of the 31,593 patients, 46% were male, and 12% had a history of VTE. After the procedure, deep vein thrombosis (DVT) was a commonly diagnosed complication (3.8% and 4.8% at 30 and 90 days, respectively). The cumulative incidence of pulmonary embolism was 0.9% and 1.2% at 30 and 90 days after the procedure, respectively. Throughout the 90-day postoperative period, females had had a slightly increased risk of DVT compared with males (30-day risk difference, 0.007; P < .01; 90-day risk difference, 0.008; P = .02). We found no sex-based differences in the risk of pulmonary embolism. Of the patients who had developed VTE at 90 days, 970 (55%) had had no prescription fill for an antiplatelet or anticoagulant. Assuming all the patients had been taking aspirin, only 15% of the patients who had developed VTE had been taking prescribed dual antiplatelet medication persistently after PVI. In addition, among the patients who had developed VTE at 90 days, females were less likely to have had a prescription fill for an anticoagulant. CONCLUSIONS: The findings from our study have demonstrated that the incidence of VTE after PVI is high, with an increased risk of deep vein thrombosis for females. We also found that females were less likely to have been prescribed an anticoagulant after PVI. Future studies are needed to characterize the variables associated with an increased risk of VTE after PVI and to identify strategies to increase dual antiplatelet therapy or anticoagulant prescription adherence to reduce the risk of VTE.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Kindell DG, Marulanda K, Caruso DM, et al. Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 36182086. doi:10.1016/j.jvsv.2022.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。